Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin in Chronic Subdural Haematoma
NCT03956368Phase 3Unknown
- Sponsor
- The Chinese University of Hong Kong
- Start
- Jan 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atorvastatin in chronic subdural hematoma (CSDH), sponsored by The Chinese University of Hong Kong. Primary endpoint: Modified Rankin Scale at 6 months. Status: unknown.
02
Drugs
atorvastatin
03
Conditions
chronic subdural hematoma (CSDH)
Beyond the preview
Go deeper on NCT03956368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03956368.